NeonMind to Present at H.C. Wainwright 2nd Annual Psychedelics Virtual Conference
NeonMind to Present at H.C. Wainwright 2nd Annual Psychedelics Virtual Conference
Vancouver, B.C. – December 02, 2021: NeonMind Biosciences Inc. (CSE: NEON) (OTCQB: NMDBF) (FRA:6UF) (“NeonMind'' or the “Company”), an integrated drug development and wellness company focusedon the potential therapeutic uses of psilocybin for treating obesity and weight management conditions,announced today that Robert Tessarolo, President and Chief Executive Officer, will participate in the H.C.Wainwright 2
nd
Annual Psychedelics Conference, being held virtually on Monday, December 6, 2021.
H.C. Wainwright 2nd Annual Psychedelics Virtual Conference Details:
Date: Monday, December 6, 2021Registration: HCW Events
The Company’s presentation will be available on-demand at the start of the conference beginning onDecember 6, 2021 at 7:00 a.m. ET. In addition to the Company’s presentation, management will beavailable to participate in one-on-one meetings with investors who are registered to attend theconference.
For more information about the conference, or to schedule a one-on-one meeting with NeonMind’smanagement team, please contact KCSA Strategic Communications at [email protected] or your H.C.Wainwright representatives directly.
About NeonMind Biosciences Inc.
NeonMind operates two divisions: (i) a pharmaceutical division engaged in drug development ofpsychedelic compounds with two lead psilocybin-based drug candidates targeting obesity; and (ii) amedical services division focused on launching specialty mental health clinics that integrate psychedelictherapeutics into traditional psychotherapy settings.
In its pharmaceutical division, NeonMind has two distinct psilocybin drug development programstargeting obesity. NeonMind’s lead candidate, NEO-001, employs psilocybin as an agonist at theserotonin 5- HT2A receptor, which is involved in the hallucinogenic effect of psychedelics. The Company’ssecond drug candidate, NEO-002, employs low-dose psilocybin as an agonist at the 5-HT2C receptor,which controls appetite.
NeonMind, and its strategic medical services partner, SRx Health Solutions, expect to launchNeonMind-branded specialty mental health clinics in Canada that incorporate evidence-backed
innovative treatments to address a variety of mental health needs. For more information on NeonMind,go to www.NeonMindBiosciences.com.
Rob Tessarolo, President & Chief Executive Officer, NeonMind Biosciences [email protected]: 416-750-3101
Investor Relations:KCSA Strategic CommunicationsScott Eckstein/Tim [email protected]: 212-896-1210
The Canadian Securities Exchange has not reviewed, approved nor disapproved the contents of this newsrelease.
Cautionary Statement Regarding Forward-Looking Statements
Certain statements contained in this press release constitute forward-looking information. Thesestatements relate to future events or NeonMind’s future performance. The use of any of the words"could", "expect", "believe", "will", "projected","estimated" and similar expressions and statementsrelating to matters that are not historical facts are intended to identify forward-looking information andare based on NeonMind’s current belief or assumptions as to the outcome and timing of such futureevents. Actual future results may differ materially. In particular, NeonMind’s drug development plans, itsability to retain key personnel, and its expectation as to the development of its intellectual property andother steps in its preclinical and clinical drug development constitute forward-looking information. Actualresults and developments may differ materially from those contemplated by forward-lookinginformation. Readers are cautioned not to place undue reliance on forward-looking information. Thestatements made in this press release are made as of the date hereof. NeonMind disclaims any intentionor obligation to publicly update or revise any forward-looking information, whether as a result of newinformation, future events or otherwise, except as may be expressly required by applicable securitieslaws.